Who Generates Higher Gross Profit? Viatris Inc. or Exelixis, Inc.

A Tale of Two Companies: Viatris Inc. vs. Exelixis, Inc.

In the competitive landscape of the pharmaceutical industry, Viatris Inc. and Exelixis, Inc. have emerged as key players. Over the past decade, Viatris has consistently outperformed Exelixis in terms of gross profit. From 2014 to 2023, Viatris's gross profit grew by approximately 75%, peaking in 2022 with a staggering $6.5 billion. In contrast, Exelixis, while showing impressive growth, increased its gross profit by nearly 7,500% over the same period, reaching $1.76 billion in 2023.

This remarkable growth trajectory of Exelixis highlights its rapid expansion and increasing market presence. However, Viatris's steady and substantial profits underscore its established dominance in the sector. As the pharmaceutical industry continues to evolve, these two companies exemplify different strategies for success: Viatris with its consistent performance and Exelixis with its dynamic growth.